| Literature DB >> 30442766 |
Johannes W Bigenzahn1, Giovanna M Collu2, Felix Kartnig1, Melanie Pieraks1, Gregory I Vladimer1, Leonhard X Heinz1, Vitaly Sedlyarov1, Fiorella Schischlik1, Astrid Fauster1,3, Manuele Rebsamen1, Katja Parapatics1, Vincent A Blomen3, André C Müller1, Georg E Winter1, Robert Kralovics1,4, Thijn R Brummelkamp1,3,5,6, Marek Mlodzik2, Giulio Superti-Furga7,8.
Abstract
In genetic screens aimed at understanding drug resistance mechanisms in chronic myeloid leukemia cells, inactivation of the cullin 3 adapter protein-encoding leucine zipper-like transcription regulator 1 (LZTR1) gene led to enhanced mitogen-activated protein kinase (MAPK) pathway activity and reduced sensitivity to tyrosine kinase inhibitors. Knockdown of the Drosophila LZTR1 ortholog CG3711 resulted in a Ras-dependent gain-of-function phenotype. Endogenous human LZTR1 associates with the main RAS isoforms. Inactivation of LZTR1 led to decreased ubiquitination and enhanced plasma membrane localization of endogenous KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog). We propose that LZTR1 acts as a conserved regulator of RAS ubiquitination and MAPK pathway activation. Because LZTR1 disease mutations failed to revert loss-of-function phenotypes, our findings provide a molecular rationale for LZTR1 involvement in a variety of inherited and acquired human disorders.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30442766 PMCID: PMC6794158 DOI: 10.1126/science.aap8210
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728